Literature DB >> 27427174

Synthesis and quality control of [(18) F]T807 for tau PET imaging.

Daniel P Holt1, Hayden T Ravert1, Robert F Dannals1.   

Abstract

The detailed synthesis and quality control of [(18) F]T807, radiotracer for tau protein aggregate imaging, are described. The radiotracer synthesis was accomplished in an average of 48 min with an average specific activity at end-of-synthesis of over 4.4 TBq/µmole (120 Ci/µmole) and an average radiochemical yield of 32%. Compliance with all standard US Pharmacopeia Chapter <823> acceptance tests was observed.
Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  PET; fluorine-18; microwave; quality control; tau

Mesh：

Substances：

Year:  2016        PMID： 27427174     DOI： 10.1002/jlcr.3425

Source DB:  PubMed          Journal:  J Labelled Comp Radiopharm        ISSN： 0362-4803            Impact factor:   1.921


  8 in total

Review 1.  Biomarkers for the Early Detection and Progression of Alzheimer's Disease.

Authors:  Scott E Counts; Milos D Ikonomovic; Natosha Mercado; Irving E Vega; Elliott J Mufson
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 2.  Radioactive synthesis of tau PET imaging agent 18F-AV-1451 and its role in monitoring the progression of Alzheimer's disease and supporting differential diagnosis.

Authors:  Wenyan Zhang; Shuoyan Xu; Hongmei Yu; Xuena Li; Zhuangzhuang Jin; Yaming Li; Zhiyi He
Journal:  Ann Nucl Med       Date:  2021-01-18       Impact factor: 2.668

Review 3.  Tau PET imaging: present and future directions.

Authors:  Laure Saint-Aubert; Laetitia Lemoine; Konstantinos Chiotis; Antoine Leuzy; Elena Rodriguez-Vieitez; Agneta Nordberg
Journal:  Mol Neurodegener       Date:  2017-02-20       Impact factor: 14.195

4.  An updated radiosynthesis of [18F]AV1451 for tau PET imaging.

Authors:  Andrew V Mossine; Allen F Brooks; Bradford D Henderson; Brian G Hockley; Kirk A Frey; Peter J H Scott
Journal:  EJNMMI Radiopharm Chem       Date:  2017-06-06

5.  Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models.

Authors:  M Catarina Silva; Fleur M Ferguson; Quan Cai; Katherine A Donovan; Ghata Nandi; Debasis Patnaik; Tinghu Zhang; Hai-Tsang Huang; Diane E Lucente; Bradford C Dickerson; Timothy J Mitchison; Eric S Fischer; Nathanael S Gray; Stephen J Haggarty
Journal:  Elife       Date:  2019-03-25       Impact factor: 8.140

Review 6.  Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer's Disease.

Authors:  Caitlin V M L Jie; Valerie Treyer; Roger Schibli; Linjing Mu
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-30

Review 7.  Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework.

Authors:  E E Wolters; A Dodich; M Boccardi; J Corre; A Drzezga; O Hansson; A Nordberg; G B Frisoni; V Garibotto; R Ossenkoppele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-06       Impact factor: 9.236

8.  Discovery and Optimization of Tau Targeted Protein Degraders Enabled by Patient Induced Pluripotent Stem Cells-Derived Neuronal Models of Tauopathy.

Authors:  M Catarina Silva; Ghata Nandi; Katherine A Donovan; Quan Cai; Bethany C Berry; Radoslaw P Nowak; Eric S Fischer; Nathanael S Gray; Fleur M Ferguson; Stephen J Haggarty
Journal:  Front Cell Neurosci       Date:  2022-03-03       Impact factor: 5.505
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.